Functional aging in fibrotic interstitial lung disease
Sabina A.Â Guler,Â Joanne M.Â Kwan,Â Janice M.Â Leung,Â NasreenÂ Khalil,Â Pearce G.Â Wilcox,Â Christopher J.Â Ryerson
European Respiratory JournalÂ 2019;Â DOI:Â 10.1183/13993003.00647-2019
Functional aging in fibrotic interstitial lung disease: The impact of frailty on adverse health outcomes
BackgroundÂ Accelerated biological and functional aging is common in fibrotic interstitial lung disease (ILD); however, their impact on adverse health outcomes has not been evaluated in this population.
MethodsÂ Patients were prospectively recruited from a specialised ILD clinic. Functional aging was determined by the frailty index (FI), and biological age by measurement of absolute telomere length (aTL) from patients' peripheral blood leukocytes. Adverse health outcomes included health-related quality of life (St George's Respiratory Questionnaire), number and length of respiratory and non-respiratory hospitalisations, medication tolerability, and time to death or lung transplantation. Multivariable models were used to determine the risks and rates of adverse health outcomes associated with the FI and aTL.
ResultsÂ 540 patients with fibrotic ILD, including 100 with idiopathic pulmonary fibrosis (IPF), provided 749 FI assessments, with 189 patients providing blood samples. The FI was strongly associated with quality of life, rate of hospitalisation, time to hospital discharge, and mortality, including with adjustment for age, sex, disease severity, and IPF diagnosis. Mortality prognostication was improved by the addition of the FI to commonly used clinical parameters and previously validated composite indices. Conversely, aTL was not associated with most adverse health outcomes. The effect of chronological age on outcomes was mediated primarily by the FI and to a lesser extent by aTL.
ConclusionsÂ Functional aging is associated with adverse health outcomes in patients with fibrotic ILD, indicating the need for consideration of the individual functional age into clinical decision-making.
This manuscript has recently been accepted for publication in theÂ European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of theÂ ERJÂ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Guler has nothing to disclose.
Conflict of interest: Dr. Kwan has nothing to disclose.
Conflict of interest: Dr. Leung has nothing to disclose.
Conflict of interest: Dr. Khalil has nothing to disclose.
Conflict of interest: Dr. Wilcox has nothing to disclose.
Conflict of interest: Dr. Ryerson has nothing to disclose.
- Copyright Â©ERS 2019
PRAKTEK Alamat baru: